167 related articles for article (PubMed ID: 38297132)
1. Modeling mutation-specific arrhythmogenic phenotypes in isogenic human iPSC-derived cardiac tissues.
Maurissen TL; Kawatou M; López-Dávila V; Minatoya K; Yamashita JK; Woltjen K
Sci Rep; 2024 Jan; 14(1):2586. PubMed ID: 38297132
[TBL] [Abstract][Full Text] [Related]
2. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets.
Shinnawi R; Shaheen N; Huber I; Shiti A; Arbel G; Gepstein A; Ballan N; Setter N; Tijsen AJ; Borggrefe M; Gepstein L
J Am Coll Cardiol; 2019 May; 73(18):2310-2324. PubMed ID: 31072576
[TBL] [Abstract][Full Text] [Related]
3. Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome.
Guo F; Sun Y; Wang X; Wang H; Wang J; Gong T; Chen X; Zhang P; Su L; Fu G; Su J; Yang S; Lai R; Jiang C; Liang P
Circ Res; 2019 Jan; 124(1):66-78. PubMed ID: 30582453
[TBL] [Abstract][Full Text] [Related]
4. Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
El-Battrawy I; Lan H; Cyganek L; Zhao Z; Li X; Buljubasic F; Lang S; Yücel G; Sattler K; Zimmermann WH; Utikal J; Wieland T; Ravens U; Borggrefe M; Zhou XB; Akin I
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29574456
[TBL] [Abstract][Full Text] [Related]
5. Isogenic Sets of hiPSC-CMs Harboring Distinct KCNH2 Mutations Differ Functionally and in Susceptibility to Drug-Induced Arrhythmias.
Brandão KO; van den Brink L; Miller DC; Grandela C; van Meer BJ; Mol MPH; de Korte T; Tertoolen LGJ; Mummery CL; Sala L; Verkerk AO; Davis RP
Stem Cell Reports; 2020 Nov; 15(5):1127-1139. PubMed ID: 33176122
[TBL] [Abstract][Full Text] [Related]
6. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.
Caballero R; Utrilla RG; Amorós I; Matamoros M; Pérez-Hernández M; Tinaquero D; Alfayate S; Nieto-Marín P; Guerrero-Serna G; Liu QH; Ramos-Mondragón R; Ponce-Balbuena D; Herron T; Campbell KF; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Delpón E; Tamargo J
Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E416-E425. PubMed ID: 28049825
[TBL] [Abstract][Full Text] [Related]
7. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture.
Lahti AL; Kujala VJ; Chapman H; Koivisto AP; Pekkanen-Mattila M; Kerkelä E; Hyttinen J; Kontula K; Swan H; Conklin BR; Yamanaka S; Silvennoinen O; Aalto-Setälä K
Dis Model Mech; 2012 Mar; 5(2):220-30. PubMed ID: 22052944
[TBL] [Abstract][Full Text] [Related]
8. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome.
Bellin M; Casini S; Davis RP; D'Aniello C; Haas J; Ward-van Oostwaard D; Tertoolen LG; Jung CB; Elliott DA; Welling A; Laugwitz KL; Moretti A; Mummery CL
EMBO J; 2013 Dec; 32(24):3161-75. PubMed ID: 24213244
[TBL] [Abstract][Full Text] [Related]
9. Allele-specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long-QT syndrome with a CALM2 mutation.
Yamamoto Y; Makiyama T; Harita T; Sasaki K; Wuriyanghai Y; Hayano M; Nishiuchi S; Kohjitani H; Hirose S; Chen J; Yokoi F; Ishikawa T; Ohno S; Chonabayashi K; Motomura H; Yoshida Y; Horie M; Makita N; Kimura T
Hum Mol Genet; 2017 May; 26(9):1670-1677. PubMed ID: 28335032
[TBL] [Abstract][Full Text] [Related]
10. Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes.
O'Hare BJ; John Kim CS; Hamrick SK; Ye D; Tester DJ; Ackerman MJ
Circ Genom Precis Med; 2020 Oct; 13(5):466-475. PubMed ID: 32940533
[TBL] [Abstract][Full Text] [Related]
11. R534C mutation in hERG causes a trafficking defect in iPSC-derived cardiomyocytes from patients with type 2 long QT syndrome.
Mesquita FCP; Arantes PC; Kasai-Brunswick TH; Araujo DS; Gubert F; Monnerat G; Silva Dos Santos D; Neiman G; Leitão IC; Barbosa RAQ; Coutinho JL; Vaz IM; Dos Santos MN; Borgonovo T; Cruz FES; Miriuka S; Medei EH; Campos de Carvalho AC; Carvalho AB
Sci Rep; 2019 Dec; 9(1):19203. PubMed ID: 31844156
[TBL] [Abstract][Full Text] [Related]
12. Drug-Mediated Shortening of Action Potentials in LQTS2 Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Duncan G; Firth K; George V; Hoang MD; Staniforth A; Smith G; Denning C
Stem Cells Dev; 2017 Dec; 26(23):1695-1705. PubMed ID: 28992755
[TBL] [Abstract][Full Text] [Related]
13. Modeling long QT syndrome type 2 on-a-chip via in-depth assessment of isogenic gene-edited 3D cardiac tissues.
Veldhuizen J; Mann HF; Karamanova N; Van Horn WD; Migrino RQ; Brafman D; Nikkhah M
Sci Adv; 2022 Dec; 8(50):eabq6720. PubMed ID: 36525500
[TBL] [Abstract][Full Text] [Related]
14. Genome sequencing in a genetically elusive multigenerational long QT syndrome pedigree identifies a novel LQT2-causative deeply intronic KCNH2 variant.
Tobert KE; Tester DJ; Zhou W; Haglund-Turnquist CM; Giudicessi JR; Ackerman MJ
Heart Rhythm; 2022 Jun; 19(6):998-1007. PubMed ID: 35144019
[TBL] [Abstract][Full Text] [Related]
15. Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant.
Garg P; Oikonomopoulos A; Chen H; Li Y; Lam CK; Sallam K; Perez M; Lux RL; Sanguinetti MC; Wu JC
J Am Coll Cardiol; 2018 Jul; 72(1):62-75. PubMed ID: 29957233
[TBL] [Abstract][Full Text] [Related]
16. A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells.
Sala L; Yu Z; Ward-van Oostwaard D; van Veldhoven JP; Moretti A; Laugwitz KL; Mummery CL; IJzerman AP; Bellin M
EMBO Mol Med; 2016 Sep; 8(9):1065-81. PubMed ID: 27470144
[TBL] [Abstract][Full Text] [Related]
17. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes.
Mehta A; Sequiera GL; Ramachandra CJ; Sudibyo Y; Chung Y; Sheng J; Wong KY; Tan TH; Wong P; Liew R; Shim W
Cardiovasc Res; 2014 Jun; 102(3):497-506. PubMed ID: 24623279
[TBL] [Abstract][Full Text] [Related]
18. Modelling the long QT syndrome with induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Zwi-Dantsis L; Caspi O; Winterstern A; Feldman O; Gepstein A; Arbel G; Hammerman H; Boulos M; Gepstein L
Nature; 2011 Mar; 471(7337):225-9. PubMed ID: 21240260
[TBL] [Abstract][Full Text] [Related]
19. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation.
Matsa E; Rajamohan D; Dick E; Young L; Mellor I; Staniforth A; Denning C
Eur Heart J; 2011 Apr; 32(8):952-62. PubMed ID: 21367833
[TBL] [Abstract][Full Text] [Related]
20. Targeted activation of human ether-à-go-go-related gene channels rescues electrical instability induced by the R56Q+/- long QT syndrome variant.
Venkateshappa R; Hunter DV; Muralidharan P; Nagalingam RS; Huen G; Faizi S; Luthra S; Lin E; Cheng YM; Hughes J; Khelifi R; Dhunna DP; Johal R; Sergeev V; Shafaattalab S; Julian LM; Poburko DT; Laksman Z; Tibbits GF; Claydon TW
Cardiovasc Res; 2023 Nov; 119(15):2522-2535. PubMed ID: 37739930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
